Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Front Immunol ; 14: 1257652, 2023.
Article in English | MEDLINE | ID: mdl-37809101

ABSTRACT

Interleukin-2 (IL-2), along with T-cell receptor (TCR) signaling, are required to control regulatory T cell (Treg) homeostasis and function in vivo. Due to the heightened sensitivity to IL-2, Tregs retain the ability to respond to low-dose or attenuated forms of IL-2, as currently being developed for clinical use to treat inflammatory diseases. While attenuated IL-2 increases Treg selectivity, the question remains as to whether a weakened IL-2 signal sufficiently enhances Treg suppressive function(s) toward disease modification. To understand this question, we characterized the in vivo activity and transcriptomic profiles of two different attenuated IL-2 muteins in comparison with wildtype (WT) IL-2. Our study showed that, in addition to favoring Tregs, the attenuated muteins induced disproportionately robust effects on Treg activation and conversion to effector Treg (eTreg) phenotype. Our data furthermore suggested that Tregs activated by attenuated IL-2 muteins showed reduced dependence on TCR signal, at least in part due to the enhanced ability of IL-2 muteins to amplify the TCR signal in vivo. These results point to a new paradigm wherein IL-2 influences Tregs' sensitivity to antigenic signal, and that the combination effect may be leveraged for therapeutic use of attenuated IL-2 muteins.


Subject(s)
Interleukin-2 , Receptors, Antigen, T-Cell , T-Lymphocytes, Regulatory , Homeostasis , Interleukin-2/genetics , Interleukin-2/metabolism , Receptors, Antigen, T-Cell/metabolism , Signal Transduction , Humans
2.
Front Immunol ; 12: 657768, 2021.
Article in English | MEDLINE | ID: mdl-33854514

ABSTRACT

Autoimmune diseases affect roughly 5-10% of the total population, with women affected more than men. The standard treatment for autoimmune or autoinflammatory diseases had long been immunosuppressive agents until the advent of immunomodulatory biologic drugs, which aimed at blocking inflammatory mediators, including proinflammatory cytokines. At the frontier of these biologic drugs are TNF-α blockers. These therapies inhibit the proinflammatory action of TNF-α in common autoimmune diseases such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease. TNF-α blockade quickly became the "standard of care" for these autoimmune diseases due to their effectiveness in controlling disease and decreasing patient's adverse risk profiles compared to broad-spectrum immunosuppressive agents. However, anti-TNF-α therapies have limitations, including known adverse safety risk, loss of therapeutic efficacy due to drug resistance, and lack of efficacy in numerous autoimmune diseases, including multiple sclerosis. The next wave of truly transformative therapeutics should aspire to provide a cure by selectively suppressing pathogenic autoantigen-specific immune responses while leaving the rest of the immune system intact to control infectious diseases and malignancies. In this review, we will focus on three main areas of active research in immune tolerance. First, tolerogenic vaccines aiming at robust, lasting autoantigen-specific immune tolerance. Second, T cell therapies using Tregs (either polyclonal, antigen-specific, or genetically engineered to express chimeric antigen receptors) to establish active dominant immune tolerance or T cells (engineered to express chimeric antigen receptors) to delete pathogenic immune cells. Third, IL-2 therapies aiming at expanding immunosuppressive regulatory T cells in vivo.


Subject(s)
Immune Tolerance , Immunomodulation , Animals , Autoantigens/immunology , Autoimmune Diseases/etiology , Autoimmune Diseases/metabolism , Autoimmune Diseases/therapy , Cell- and Tissue-Based Therapy , Dendritic Cells/immunology , Dendritic Cells/metabolism , Humans , Immune Tolerance/drug effects , Immunologic Factors , Immunomodulation/drug effects , Immunotherapy/methods , Interleukin-2/metabolism , Interleukin-2/pharmacology , Interleukin-2/therapeutic use , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Vaccines/administration & dosage , Vaccines/immunology
3.
Front Immunol ; 11: 1106, 2020.
Article in English | MEDLINE | ID: mdl-32582190

ABSTRACT

Among all T and NK cell subsets, regulatory T (Treg) cells typically respond to the lowest concentrations of IL-2 due to elevated surface expression of the IL-2R alpha chain (IL2RA; CD25) and the high affinity IL-2 receptor (IL-2R) complex. This enhanced sensitivity forms the basis for low-dose (LD) IL-2 therapy for the treatment of inflammatory diseases, where efficacy correlates with increased Treg cell number and expression of functional markers. Despite strong preclinical support for this approach, moderate and variable clinical efficacy has raised concerns that adequate Treg selectivity still cannot be achieved with LD IL-2, and/or that doses are too low to stimulate effective Treg-mediated suppression within tissues. This has prompted development of IL-2 variants with greater Treg selectivity, achieved through attenuated affinity for the signaling chains of the IL-2R complex (IL2RB or CD122 and IL2RG or CD132) and, consequently, greater reliance on high CD25 levels for full receptor binding and signaling. While certain IL-2 variants have advanced to the clinic, it remains unknown if the full range of IL-2R signaling potency and Treg-selectivity observed with low concentrations of wildtype IL-2 can be sufficiently recapitulated with attenuated IL-2 muteins at high concentrations. Using a panel of engineered IL-2 muteins, we investigated how a range of IL-2R signaling intensity, benchmarked by the degree of STAT5 phosphorylation, relates to biologically relevant Treg cell responses such as proliferation, lineage and phenotypic marker expression, and suppressor function. Our results demonstrate that a surprisingly wide dynamic range of IL-2R signaling intensity leads to productive biological responses in Treg cells, with negligible STAT5 phosphorylation associating with nearly complete downstream effects such as Treg proliferation and suppressor activity. Furthermore, we show with both in vitro and humanized mouse in vivo systems that different biological responses in Treg cells require different minimal IL-2R signaling thresholds. Our findings suggest that more than minimal IL-2R signaling, beyond that capable of driving Treg cell proliferation, may be required to fully enhance Treg cell stability and suppressor function in vivo.


Subject(s)
Interleukin-2/immunology , Lymphocyte Activation/immunology , T-Lymphocytes, Regulatory/immunology , Animals , Humans , Interleukin-2/metabolism , Mice , Protein Binding , Protein Engineering , Recombinant Proteins/immunology , Recombinant Proteins/metabolism , Structure-Activity Relationship
4.
J Immunol ; 191(5): 2205-16, 2013 Sep 01.
Article in English | MEDLINE | ID: mdl-23894201

ABSTRACT

TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23. Extensive studies of mice that lack TYK2 expression indicate that the IFN-α, IL-12, and IL-23 pathways, but not the IL-6 or IL-10 pathways, are compromised. In contrast, there have been few studies of the role of TYK2 in primary human cells. A genetic mutation at the tyk2 locus that results in a lack of TYK2 protein in a single human patient has been linked to defects in the IFN-α, IL-6, IL-10, IL-12, and IL-23 pathways, suggesting a broad role for TYK2 protein in human cytokine responses. In this article, we have used a panel of novel potent TYK2 small-molecule inhibitors with varying degrees of selectivity against other JAK kinases to address the requirement for TYK2 catalytic activity in cytokine pathways in primary human cells. Our results indicate that the biological processes that require TYK2 catalytic function in humans are restricted to the IL-12 and IL-23 pathways, and suggest that inhibition of TYK2 catalytic activity may be an efficacious approach for the treatment of select autoimmune diseases without broad immunosuppression.


Subject(s)
Cytokines/immunology , Protein Kinase Inhibitors/pharmacology , Signal Transduction/immunology , TYK2 Kinase/immunology , TYK2 Kinase/metabolism , Animals , Cytokines/metabolism , Humans , Immunoblotting , Interleukin-12/immunology , Interleukin-12/metabolism , Interleukin-23/immunology , Interleukin-23/metabolism , Mice , Signal Transduction/drug effects
5.
PLoS One ; 6(10): e25038, 2011.
Article in English | MEDLINE | ID: mdl-22022372

ABSTRACT

Genome-wide association studies (GWAS) in several populations have demonstrated significant association of the IL23R gene with IBD (Crohn's disease (CD) and ulcerative colitis (UC)) and psoriasis, suggesting that perturbation of the IL-23 signaling pathway is relevant to the pathophysiology of these diseases. One particular variant, R381Q (rs11209026), confers strong protection against development of CD. We investigated the effects of this variant in primary T cells from healthy donors carrying IL23R(R381) and IL23R(Q381) haplotypes. Using a proprietary anti-IL23R antibody, ELISA, flow cytometry, phosphoflow and real-time RT-PCR methods, we examined IL23R expression and STAT3 phosphorylation and activation in response to IL-23. IL23R(Q381) was associated with reduced STAT3 phosphorylation upon stimulation with IL-23 and decreased number of IL-23 responsive T-cells. We also observed slightly reduced levels of proinflammatory cytokine secretion in IL23R(Q381) positive donors. Our study shows conclusively that IL23R(Q381) is a loss-of-function allele, further strengthening the implication from GWAS results that the IL-23 pathway is pathogenic in human disease. This data provides an explanation for the protective role of R381Q in CD and may lead to the development of improved therapeutics for autoimmune disorders like CD.


Subject(s)
Amino Acid Substitution/genetics , Genetic Predisposition to Disease , Inflammatory Bowel Diseases/genetics , Polymorphism, Single Nucleotide/genetics , Receptors, Interleukin/genetics , Amino Acid Sequence , Arginine/genetics , Cell Line, Transformed , Clone Cells , Conserved Sequence/genetics , Humans , Interleukin-23/pharmacology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Lymphocyte Count , Models, Biological , Molecular Sequence Data , Phosphorylation/drug effects , Receptors, Interleukin/chemistry , STAT Transcription Factors/metabolism , Species Specificity , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , Tissue Donors
6.
EMBO J ; 27(13): 1896-906, 2008 Jul 09.
Article in English | MEDLINE | ID: mdl-18548009

ABSTRACT

The mitogen-activated protein kinases (MAPKs) ERK1/2, p38, and JNK are thought to determine survival-versus-death fate in developing thymocytes. However, this view was challenged by studies using 'MEK1-ERK1/2-specific' pharmacological inhibitors, which block both positive and negative selection. Recently, these inhibitors were also shown to affect MEK5, an upstream activator of ERK5, another class of MAPK with homology to ERK1/2. To define the contribution of the MEK5-ERK5 pathway in T-cell development, we retrovirally expressed dominant-negative or constitutively activated form of MEK5 to inhibit or activate the MEK5-ERK5 pathway. We demonstrate that MEK5 regulates apoptosis of developing thymocytes but has no function in positive selection. ERK5 activity correlates with the levels of Nur77 family members but not that of Bim, two effector pathways of thymocyte apoptosis. These results illustrate the critical involvement of the MEK5-ERK5 pathway in thymocyte development distinct from that of ERK1/2 and highlight the importance of the MAPK network in mediating differential effects pertaining to T-cell differentiation and apoptosis.


Subject(s)
Apoptosis , MAP Kinase Kinase 5/metabolism , Mitogen-Activated Protein Kinase 7/metabolism , Receptors, Antigen, T-Cell/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , Animals , Cells, Cultured , MAP Kinase Signaling System , Mice , Mice, Inbred BALB C , Thymus Gland/cytology
7.
Curr Opin Immunol ; 19(5): 510-5, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17656079

ABSTRACT

Recent investigations have solidified the importance of negative selection in controlling autoimmunity. Loss of autoimmune regulator (AIRE), required for thymic stromal-cell differentiation and thymic expression of peripheral antigens, results in multi-organ autoimmunity. Mice with AIRE/Foxp3 double mutations suffer from exacerbated autoimmunity when compared with mice with only one mutation, supporting the important contributions of both central and peripheral tolerance. In thymocytes, Cbl is a negative regulator of thymocyte apoptosis while MINK, a MEKK kinase, is required for negative selection. This is consistent with the requirement of JNK, p38 and possibly ERK5 MAP kinases in thymocyte apoptosis. ERK5 induces the Nur77 orphan steroid receptor family members. In cell lines, Nur77 interaction with Bcl-2 turns Bcl-2 into a pro-apoptotic molecule. This and other possibilities will be discussed to explain the unresolved finding that negative selection is defective in Bim(-/-) but is not efficiently blocked in Bcl-2 transgenic mice.


Subject(s)
Apoptosis , Autoimmunity , Self Tolerance , T-Lymphocytes/immunology , Thymus Gland/immunology , Transcription Factors/metabolism , Animals , Apoptosis Regulatory Proteins/metabolism , Bcl-2-Like Protein 11 , Clonal Deletion , Humans , Membrane Proteins/metabolism , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , Thymus Gland/cytology , Thymus Gland/metabolism , AIRE Protein
8.
J Biol Chem ; 282(31): 22786-92, 2007 Aug 03.
Article in English | MEDLINE | ID: mdl-17553783

ABSTRACT

Fas-associated death domain (FADD) is an adaptor molecule for the death receptor subfamily of the tumor necrosis factor receptor superfamily, but it is also required for cell proliferation. Cell cycle-specific regulation of FADD phosphorylation plays an important role in FADD proliferative function since mice with a mutant form of FADD mimicking constitutive phosphorylation at serine 191 (FADD-D) exhibit defective T cell proliferation. Here we characterized these mice in detail and found that T cell development in 2-4-week-old mice is relatively normal, although mature FADD-D T cells manifest defective G(0) and G(1) to S transition with abnormalities in regulation of p130, p27 degradation, retinoblastoma protein phosphorylation, and CDK2 kinase activity. These downstream defects are further associated with the failure to up-regulate the forkhead box M1 cell cycle transcription factor, FoxM1. FADD-D protein is also mislocalized during cell cycle progression. Thus, regulation of FADD phosphorylation is crucial for proper cell cycle entry.


Subject(s)
Fas-Associated Death Domain Protein/chemistry , Fas-Associated Death Domain Protein/genetics , Mutation , Animals , Apoptosis , Cell Cycle , Cell Proliferation , Flow Cytometry , Gene Expression Regulation , Immunoprecipitation , Mice , Mice, Transgenic , Microscopy, Fluorescence , Phosphorylation , Receptors, Death Domain/metabolism , Retinoblastoma Protein/metabolism
9.
Mol Cell Biol ; 25(19): 8553-66, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16166637

ABSTRACT

The ERK5 mitogen-activated protein kinase (MAPK) differs from other MAPKs in possessing a potent transcriptional activation domain. ERK5-/- embryos die from angiogenic defects, but the precise physiological role of ERK5 remains poorly understood. To elucidate molecular functions of ERK5 in the development of vasculature and other tissues, we performed gene profile analyses of erk5-/- mouse embryos and erk5-/- fibroblast cells reconstituted with ERK5 or ERK5(1-740), which lacks the transactivation domain. These experiments revealed several potential ERK5 target genes, including a proapoptotic gene bnip3, known angiogenic genes flt1 and lklf (lung Krüppel-like factor), and genes that regulate cardiovascular development. Among these, LKLF, known for its roles in angiogenesis, T-cell quiescence, and survival, was found to be absolutely dependent on ERK5 for expression in endothelial and T cells. We show that ERK5 drives lklf transcription by activating MEF2 transcription factors. Expression of erk5 short hairpin or a dominant-negative form of the ERK5 upstream activator, MEK5, in T cells led to downregulation of LKLF, increased cell size and upregulation of activation markers. Thus, through its kinase and transcriptional activation domains, ERK5 regulates transcriptional responses of cell survival and quiescence critical for angiogenesis and T-cell function.


Subject(s)
Gene Expression Regulation , Kruppel-Like Transcription Factors/metabolism , Mitogen-Activated Protein Kinase 7/physiology , Transcription, Genetic , Amino Acid Motifs , Animals , Apoptosis , Base Sequence , Cardiovascular System/embryology , Cell Size , Cell Survival , Chromatin Immunoprecipitation , Cloning, Molecular , DNA/chemistry , DNA, Complementary/metabolism , Down-Regulation , Fibroblasts/metabolism , Flow Cytometry , Genes, Dominant , Genes, Reporter , Humans , Hypoxia , Immunoblotting , In Situ Hybridization , Mice , Mice, Transgenic , Mitogen-Activated Protein Kinase 7/metabolism , Molecular Sequence Data , Neovascularization, Pathologic , Oligonucleotide Array Sequence Analysis , Protein Structure, Tertiary , RNA, Small Interfering/metabolism , Retroviridae/genetics , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , Time Factors , Tissue Distribution , Transcriptional Activation , Up-Regulation
10.
Immunity ; 18(4): 513-21, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12705854

ABSTRACT

FADD is an adaptor known to transmit apoptotic signals from members of the tumor necrosis factor receptor family. We show here that FADD has a domain implicated in cell proliferation. Mice bearing the Asp mutation in the serine 191 phosphorylation site are runted and anemic and display splenomegaly. Apoptosis is unimpaired in these mice, but they exhibit many immune developmental problems indicative of proliferative defects. Mutant FADD T cells are defective in cell cycle progression, suggesting that regulation of phosphorylation at serine 191 is essential for growth/proliferation. Remarkably, serine 191 is conserved among mammalian FADD proteins, but this C-terminal region is absent in lower organisms, suggesting that FADD acquired a domain during evolution, rendering it a "proliferation-apoptosis coupler" that balances cell proliferation and apoptosis.


Subject(s)
Adaptor Proteins, Signal Transducing , Carrier Proteins/physiology , Amino Acid Sequence , Anemia/etiology , Animals , Apoptosis , Carrier Proteins/chemistry , Cell Cycle , Cell Division , Fas-Associated Death Domain Protein , Mice , Molecular Sequence Data , Splenomegaly/etiology , Structure-Activity Relationship , T-Lymphocytes/physiology
11.
Curr Opin Immunol ; 15(2): 209-16, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12633672

ABSTRACT

Recent investigations have provided important insights into how signaling through the antigen receptors determines whether a cell survives or dies. In T cells, Grb2 and MAP kinases play essential roles in differentiating between apoptotic and survival signals. The PTEN phosphatase and Bim, a pro-apoptotic Bcl-2 family member, regulate apoptosis in both T and B cells. In B cells, antigen receptor-mediated death can be rescued by co-stimulation, in which the roles of protein kinase C and BAFF, a TNF family member, have been recently elucidated. In a recently identified mechanism of regulating inflammation, receptors such as c-mer and glycoproteins such as MFG-E8 were found to participate in the clearance of apoptotic cells.


Subject(s)
Apoptosis/physiology , Lymphocytes/physiology , Animals , Lymphocytes/cytology , Mice , Mice, Transgenic , Models, Biological , Receptors, Antigen, B-Cell/genetics , Receptors, Antigen, B-Cell/physiology , Receptors, Antigen, T-Cell/genetics , Receptors, Antigen, T-Cell/physiology , Signal Transduction/physiology
12.
J Biol Chem ; 277(45): 43344-51, 2002 Nov 08.
Article in English | MEDLINE | ID: mdl-12221099

ABSTRACT

During angiogenesis, endothelial cells undergo proliferation, reorganization, and stabilization to establish a mature vascular network. This process is critical for establishing a functional circulatory system during development and contributes to the pathological process of tumor growth. Here we report that embryos deficient for the ERK5 MAPK die between embryonic days 10.5 and 11.5 with angiogenic failure and cardiovascular defects. We show that ERK5 deficiency leads to an increased expression of the vascular endothelial growth factor (VEGF), dysregulation of which has been shown to impede angiogenic remodeling and vascular stabilization. Our data also reveal that ERK5 negatively regulates transcription from the vegf locus during hypoxic responses. Importantly, ERK5 is required at an earlier developmental stage than p38alpha, and p38alpha does not compensate for ERK5 deficiency. These results demonstrate that ERK5 plays a specific role in the regulation of early angiogenesis.


Subject(s)
Endothelial Growth Factors/genetics , Intercellular Signaling Peptides and Proteins/genetics , Lymphokines/genetics , Mitogen-Activated Protein Kinases/metabolism , Neovascularization, Physiologic/physiology , Repressor Proteins/metabolism , Animals , Cell Hypoxia , Endothelial Growth Factors/antagonists & inhibitors , Exons , Female , Fetal Death , Gene Expression Regulation, Developmental , Gestational Age , Introns , Lymphokines/antagonists & inhibitors , Mice , Mice, Knockout , Mitogen-Activated Protein Kinase 7 , Mitogen-Activated Protein Kinases/deficiency , Mitogen-Activated Protein Kinases/genetics , Pregnancy , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , Yolk Sac/blood supply , Yolk Sac/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...